Search company, investor...

Founded Year



Seed VC | Alive

Total Raised


Last Raised

$670K | 7 yrs ago

About Signatope

Signatope develops protein biomarker assays using mass spectrometry-based immunoassays. It develops protein assays that are capable of detecting and quantifying biomarkers for organ damage and drug interactions in blood, urine, and tissue. It offers analytical services for clients in the pharmaceutical and chemical industries. It was founded in 2016 and is based in Reutlingen, Germany.

Headquarters Location

Markwiesenstr. 55

Reutlingen, D-72770,


+49 7121 51530802



Latest Signatope News

Signatope Partners With CPATH to Apply Immuno-MS Approach to Drug Toxicity Testing

Sep 25, 2018

Premium NEW YORK (GenomeWeb) – Protein analytics firm Signatope is applying its amino acid motif-specific antibody technology to identifying and measuring protein biomarkers for drug development. Get the full story with GenomeWeb Premium

Signatope Frequently Asked Questions (FAQ)

  • When was Signatope founded?

    Signatope was founded in 2016.

  • Where is Signatope's headquarters?

    Signatope's headquarters is located at Markwiesenstr. 55, Reutlingen.

  • What is Signatope's latest funding round?

    Signatope's latest funding round is Seed VC.

  • How much did Signatope raise?

    Signatope raised a total of $670K.

  • Who are the investors of Signatope?

    Investors of Signatope include High-Tech Grunderfonds.



CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.